Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 248

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 248
---
 fails to comply with regulatory requirements.

•

Liminatus’s brand and reputation are critical to its success, and any publicity, regardless of accuracy, that portrays Liminatus negatively could adversely impact operating results.

•

The risks and costs to Iris if the Business Combination is not completed, including the risk of diverting management’s focus and resources from other businesses combination opportunities, which could result in Iris being unable to effect a business combination within the completion window, which would require Iris to liquidate.

•

The risk that Iris’s stockholders may object to and challenge the Business Combination and take action that may prevent or delay the closing, including by voting against the Business Combination Proposal.

•

The terms of the Business Combination Agreement provide that Iris will not have any surviving remedies against Liminatus or its equityholders after the closing to recover for losses as a result of any inaccuracies or breaches of Liminatus’s representations, warranties, or covenants set forth in the Business Combination Agreement.

•

The risk that the potential benefits of the Business Combination may not be fully achieved, or may not be achieved within the expected time frame.

•

The fees and expenses associated with completing the Business Combination will be significant.

•

The potential that a significant number of Iris’s stockholders elect to redeem their shares prior to the consummation of the Business Combination, which would reduce the amount of cash available following the closing.

•

The challenges associated with preparing Liminatus for the applicable disclosure and Nasdaq listing requirements.

•

Liminatus will require additional capital to complete the research and development and potential commercialization of its intellectual property assets. No assurance can be given that such additional capital will be available on terms acceptable to Liminatus, if at all. If Liminatus is unable to raise capital when needed or on acceptable terms, Liminatus could be forced to delay, reduce, or eliminate its planned research and development programs or any future commercialization efforts.

•

The risk that the Transactions might not be consummated or completed in a timely manner or that the closing might not occur despite Iris’s best efforts, including by reason of a failure to obtain the approval of Iris’s stockholders, litigation challenging the Business Combination or that an adverse judgment granting permanent injunctive relief cold indefinitely enjoin the consummation of the Business Combination.

<div align='center'>117</div>

TABLE OF CONTENTS

•

Continuing coronavirus outbreaks may have a material adverse effect on Liminatus’s business, liquidity, financial condition and results of operations.

•

Safety risks associated with the products